Inogen (INGN) Q3 2026 Earnings Call Transcript

Inogen reported Q3 2026 results showing mixed performance with U.S. sales growth of 3.8% driven by new products, but international sales declined 9% due to European customer softness. The company divested its U.S. oxygen rental business for $24.8 million and announced a $20 million cost-reduction program to accelerate profitability. New CEO Andrew Reding outlined plans to streamline operations and expand into adjacent respiratory markets with Aurora and Voxi products. Full-year revenue guidance is $298-301 million with adjusted net loss of $7-8 million.